Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AZD 0120

Next Previous
Drug Profile

AZD 0120

Alternative Names: AZD-0120; BCMA-Antigen X Bispecific CAR-Modified T Cells-Gracell-Biotechnology; BCMA-Antigen X bispecific CAR-T cells; BCMA/CD19 dual-target CAR-T cell immunotherapy - Gracell Biotechnology; BCMA/CD19 dual-targeting CAR-T therapy; CD19-BCMA CAR-T cells; Dual CAR-BCMA-19; FasTCAR-T GC012F; GC 012; GC-012F

Latest Information Update: 16 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gracell Biotechnology
  • Developer AstraZeneca; Gracell Biotechnology
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Amyloid light-chain amyloidosis; Multiple myeloma; Systemic lupus erythematosus
  • Phase I Autoimmune disorders; Multiple sclerosis
  • Phase 0 Myasthenia gravis
  • No development reported Non-Hodgkin's lymphoma

Most Recent Events

  • 06 Feb 2026 AstraZeneca plans phase III DURGA-4 trial in Multiple Myeloma (Second-line therapy and greater) in US, Australia, Brazil, Canada, France, Germany, Italy, Japan, Poland, South Korea, Spain, Taiwan and United Kingdom in February 2026 (NCT07391657)
  • 23 Jan 2026 Huashan Hospital plans a phase 0 trial for Multiple Sclerosis (Treatment resistant) in China (IV Infusion) (NCT07364487)
  • 09 Jan 2026 Phase-I clinical trials in Autoimmune disorders in Australia (Parenteral) (NCT07295847)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top